EN
HI
Summary
As of 4 Oct, 2026, Novelix Pharmaceuticals stock price is ₹70. During the trading session, the stock has moved between an intraday low of ₹66.01 and an intraday high of ₹70.50. Over the last 52 weeks, Novelix Pharmaceuticals has traded between ₹38.00 and ₹92.00.
The stock has recorded a trading volume of 246 shares,. Its Average Traded Price (ATP) is ₹69.97, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 9 @ ₹70.00.
Novelix Pharmaceuticals has an upper circuit limit of ₹77.00 and a lower circuit limit of ₹63.00. The total value traded stands at ₹17212.62, and the delivery percentage for the day is 0%.
The stock is currently traded with a market lot size of 1. Novelix Pharmaceuticals also offers a dividend yield of 0%.
Novelix Pharmaceuticals Share Price Chart
Novelix Pharmaceuticals Share Key Metrics
Volume
246.00
Market Cap
199.29 CR
LTQ@LTP
9@70.00
ATP
69.97
Var Margin
25 %
Circuit Range
63-77
Delivery %
0 %
Value
17212.62
ASM/GSM
No
Market Lot
1
Novelix Pharmaceuticals Resistance and Support
Pivot 69.78
Resistance
First Resistance
75.21
Second Resistance
80.43
Third Resistance
85.86
Support
First Support
64.56
Second Support
59.13
Third Support
53.91
Novelix Pharmaceuticals Historical Data
| Day | Open | Close | Change(%) | Day High | Day Low |
|---|---|---|---|---|---|
| Thu Oct 01 2026 | 70.5 | 70 | 0.00% | 70.5 | 66.01 |
| Wed Sep 30 2026 | 75 | 70 | -0.07% | 75 | 64.34 |
| Tue Sep 29 2026 | 72 | 70.05 | 0.04% | 74 | 70 |
Novelix Pharmaceuticals Corporate Actions
| Date | Agenda |
|---|---|
| 2026-08-29 | Others |
| 2026-08-13 | Quarterly Results |
| 2026-06-04 | Preferential Issue of shares & Others |
| 2026-05-29 | Audited Results & Preferential issue |
| 2026-02-12 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-08-14 | Quarterly Results & A.G.M. |
| 2025-06-24 | Others |
| 2025-05-27 | Audited Results |
| 2025-02-12 | Quarterly Results |
| 2024-11-13 | Quarterly Results & Others |
| 2024-10-21 | To consider issue of Warrants |
| 2024-10-14 | To consider issue of Warrants |
| 2024-09-02 | Others |
| 2024-08-08 | Quarterly Results |
| 2024-03-05 | Preferential issue of shares |
Novelix Pharmaceuticals News
Novelix Pharmaceuticals Ltd - 536565 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Novelix Pharmaceuticals Limited (formerly Trimurthi Limited): Proceedings of the 32nd AGM held on 30th September 2026.
Sep 30 2026 18:19:38
Novelix Pharmaceuticals Management
| Name | Position |
|---|---|
| Venkateshwarlu Pulluru | Whole Time Director |
| Janardhan Das Kabra | Non Executive Independent Director |
Novelix Pharmaceuticals FAQs
The Buying Price of Novelix Pharmaceuticals share is 70 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Novelix Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Novelix Pharmaceuticals, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Novelix Pharmaceuticals shares is 0. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Novelix Pharmaceuticals shares is 0. Useful to assess the stock's value relative to its book value.
To assess Novelix Pharmaceuticals’s valuation compare Sector P/E, P/B which are 63.28 & 1.7 with sector averages, along with growth rates and financial metrics.
The Market Cap of Novelix Pharmaceuticals is 199.29 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Novelix Pharmaceuticals share price is 92.00 & 38.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Novelix Pharmaceuticals belongs to the Miscellaneous sector.
Open Your Free
Demat Account Now!
AMC for First Year- Auto Square Off Charges
13 Lakh+ Clients
Expert-Backed
Premium Tools
Open Your Free
Demat Account Now!
- AMC For First Year
- Account Opening Fee
- 13 Lakh+ Clients
- Expert-Backed
- Premium Tools
Invest in NOVELIX
